Login / Signup

Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.

Hela-Felicitas PetereitHayrettin TumaniUwe K Zettl
Published in: Therapeutic advances in neurological disorders (2021)
Keyphrases
  • immune response
  • coronavirus disease
  • sars cov
  • dendritic cells
  • toll like receptor
  • binding protein